X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. REDDYS LAB - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. REDDYS LAB AUROBINDO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 18.0 27.6 65.0% View Chart
P/BV x 5.8 2.8 204.9% View Chart
Dividend Yield % 0.4 1.0 35.7%  

Financials

 AUROBINDO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
AUROBINDO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,5414,383 35.1%   
Low Rs5822,750 21.2%   
Sales per share (Unadj.) Rs237.5920.1 25.8%  
Earnings per share (Unadj.) Rs33.9126.1 26.9%  
Cash flow per share (Unadj.) Rs40.6183.0 22.2%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.20.6 42.0%  
Book value per share (Unadj.) Rs120.6685.8 17.6%  
Shares outstanding (eoy) m585.17170.61 343.0%   
Bonus/Rights/Conversions PREFESOP-  
Price / Sales ratio x4.53.9 115.3%   
Avg P/E ratio x31.328.3 110.8%  
P/CF ratio (eoy) x26.219.5 134.2%  
Price / Book Value ratio x8.85.2 169.2%  
Dividend payout %7.415.9 46.5%   
Avg Mkt Cap Rs m621,041608,481 102.1%   
No. of employees `00013.321.7 61.3%   
Total wages/salary Rs m15,50831,874 48.7%   
Avg. sales/employee Rs Th10,457.67,244.4 144.4%   
Avg. wages/employee Rs Th1,167.11,470.9 79.3%   
Avg. net profit/employee Rs Th1,491.6992.8 150.2%   
INCOME DATA
Net Sales Rs m138,961156,978 88.5%  
Other income Rs m1,6632,693 61.7%   
Total revenues Rs m140,624159,671 88.1%   
Gross profit Rs m32,05634,587 92.7%  
Depreciation Rs m3,9269,705 40.5%   
Interest Rs m2,568824 311.6%   
Profit before tax Rs m27,22526,751 101.8%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,4445,237 142.1%   
Profit after tax Rs m19,82021,514 92.1%  
Gross profit margin %23.122.0 104.7%  
Effective tax rate %27.319.6 139.7%   
Net profit margin %14.313.7 104.1%  
BALANCE SHEET DATA
Current assets Rs m100,015118,201 84.6%   
Current liabilities Rs m74,75968,368 109.3%   
Net working cap to sales %18.231.7 57.3%  
Current ratio x1.31.7 77.4%  
Inventory Days Days10760 179.0%  
Debtors Days Days11097 113.1%  
Net fixed assets Rs m52,35072,265 72.4%   
Share capital Rs m585853 68.6%   
"Free" reserves Rs m67,707111,548 60.7%   
Net worth Rs m70,567117,009 60.3%   
Long term debt Rs m8,47210,690 79.3%   
Total assets Rs m156,994200,104 78.5%  
Interest coverage x11.633.5 34.7%   
Debt to equity ratio x0.10.1 131.4%  
Sales to assets ratio x0.90.8 112.8%   
Return on assets %14.311.2 127.7%  
Return on equity %28.118.4 152.8%  
Return on capital %37.721.6 174.8%  
Exports to sales %51.046.3 110.3%   
Imports to sales %18.89.0 210.6%   
Exports (fob) Rs m70,92772,618 97.7%   
Imports (cif) Rs m26,19314,050 186.4%   
Fx inflow Rs m71,01575,405 94.2%   
Fx outflow Rs m28,79927,115 106.2%   
Net fx Rs m42,21648,290 87.4%   
CASH FLOW
From Operations Rs m17,59640,476 43.5%  
From Investments Rs m-13,801-19,421 71.1%  
From Financial Activity Rs m-198-17,009 1.2%  
Net Cashflow Rs m3,5974,046 88.9%  

Share Holding

Indian Promoters % 54.1 25.5 212.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.4 147.2%  
FIIs % 27.7 35.3 78.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.2 15.3 66.7%  
Shareholders   69,601 75,885 91.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS